Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDX-014
- Development stage
- Discontinued
- Lead developer
- Celldex Therapeutics
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CDX-014 is an antibody-drug conjugate (ADC) designed for the treatment of cancer. It consists of a fully human immunoglobulin G1 monoclonal antibody targeting T-cell immunoglobulin mucin domain-containing protein 1 (TIM-1), a surface marker highly expressed in renal cell carcinoma and ovarian carcinoma. The antibody is covalently linked to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline linker. Upon binding to TIM-1 on tumor cells and internalization, MMAE is released inside the cell, leading to inhibition of tubulin polymerization and subsequent cytotoxic death of the cancer cell. CDX-014 was developed by Celldex Therapeutics using XenoMouse technology originally from Amgen/CuraGen Corporation. Clinical trials have shown manageable toxicity and early signs of antitumor activity in advanced refractory renal cell carcinoma[1][3][4][5].
- Other names
- antibody-drug conjugate anti-TIM-1-vcMMAE
02
Targets
TIM-1 (T-cell immunoglobulin and mucin domain-containing protein 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on CDX-014.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDX-014.